Abbott's Solvay Pharma Buy More Salve Than Cure

Abbott Laboratories announced plans to acquire Solvay's pharmaceutical business for $6.6 billion Sept. 28, a strategic maneuver that seems as much about adding revenues to Abbott's top-line as addressing long-term challenges in the pharmaceutical pipeline